helicobacter%20pylori%20infection
HELICOBACTER PYLORI INFECTION
Helicobacter pylori is a spiral-shaped gram-negative bacterium involved in the development of gastritis, duodenal and gastric ulcers, and gastric cancer.
Infection is strongly associated with the development of gastric epithelial and lymphoid malignancies.
Acute infection is mostly asymptomatic and is acquired through human-to-human contact via gastro-oral and fecal-oral routes.
Adaptability in gastric conditions and production of urease allow it to colonize the stomach.

Definition

Dyspepsia

  • Presence of ≥1 of the following: Bothersome postprandial fullness, early satiation, epigastric pain and/or epigastric burning
  • No evidence of structural disease (including at upper endoscopy) that is likely to explain the symptoms (functional or non-ulcer dyspepsia)
  • Symptoms were present within the last 3 months with onset ≥6 months prior to diagnosis (Rome III criteria)
  • Though the relationship between functional dyspepsia and Helicobacter pylori (H pylori) is unclear, improvement of functional dyspepsia symptoms was seen with elimination of H pylori infection

Etiology

Helicobacter pylori

  • A spiral-shaped Gram-negative bacterium involved in the development of gastritis, duodenal and gastric ulcers, and gastric cancer
    • H pylori gastritis may decrease or increase acid secretion and cause dyspeptic symptoms  
    • Up to 90-95% of patients with nonsteroidal anti-inflammatory drug (NSAID)-related duodenal ulcers and 80% of patients with non-NSAID-related gastric ulcers are infected
    • Infection is strongly associated with the development of gastric epithelial and lymphoid malignancies
  • Acute infection is mostly asymptomatic and is acquired through human-to-human contact via gastro-oral and fecal-oral routes
  • Adaptability in gastric conditions and production of urease allow it to colonize the stomach
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 May 2014

New drug applications approved by US FDA as of 15-30 May which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

28 Apr 2017
Silymarin does not appear to be significantly better than placebo in reducing disease activity by 30 percent or more in patients with nonalcoholic steatohepatitis (NASH), according to the results of a trial.
28 Aug 2017
Relamorelin appears to be effective in reducing core symptoms of gastroparesis, as well as improving overall composite symptom severity score and accelerated gastric emptying, in diabetic patients with moderate to severe gastroparesis, according to the results of a phase IIB trial.
Chistopher S Pokorny, 01 Dec 2013

Angela, a 28-year-old woman who is 14 weeks pregnant, presents to her GP with a 2-month history of intermittent rectal bleeding. Over this period, she has been passing bright blood on to her toilet paper, and at times into the toilet bowl. In addition, her stools are looser than in the past, and she reports occasional urgency. There has been no abdominal pain or weight loss. Her general health is good, and she is not taking any regular medications. There is no relevant family history.